

<b>REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL</b>	<i>Application No.:</i> 10/583,877
Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	
<i>Filing Date:</i> June 21, 2006	
<i>First Named Inventor:</i> J. Henry Ellis	
<i>Group Art Unit:</i> 1649	
<i>Examiner:</i> Stacey MacFarlane	
<i>Attorney Docket No.:</i> PB60608	
<b>Confirmation No. 8672</b> <b>Electronically Filed on:</b> July 7, 2010	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

**1. Submission required under 37 C.F.R. § 1.114**

- a.  Previously submitted
  - i.  Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_.  
(Any unentered amendment(s) referred to above will be entered)
  - ii.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_.
  - iii.  Other \_\_\_\_\_
- b.  Enclosed
  - i.  Amendment/Reply 9 pages
  - ii.  Affidavit(s)/Declaration(s) \_\_\_\_\_ pages
  - iii.  Information Disclosure Statement (IDS) \_\_\_\_\_ pages
  - iv.  Form PTO 1449 \_\_\_\_\_ pgs. & \_\_\_\_\_ references attached
  - v.  Other \_\_\_\_\_

**2. Miscellaneous**

- a.  Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c)  
for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(I) required)
- b.  Other \_\_\_\_\_

**3. FEES** The RCE fee under 37 C.F.R. § 1.117(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a.  The Director is hereby authorized to charge the following fees or credit any overpayments, to  
**Deposit Account No. 19-2570.**
  - General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(g)(3))
  - i.  RCE fee required under 37 C.F.R. § 1.17(e). **\$810.00**
  - ii.  (3 ) Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) **\$1110.00**
  - iii.  Additional Fees
- iv.  **Total Fee to be charged to Deposit Account 19-2570      \$1920.00**

**CORRESPONDENCE ADDRESS**

**RESPECTFULLY SUBMITTED,**

*Address* GLAXOSMITHKLINE  
Corporate Intellectual Property – UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
*Telephone* (610) 270-6887 *Facsimile* (610) 270-5090

*Signature* /Jonathan M. Dermott/ \_\_\_\_\_  
*NAME* Jonathan M. Dermott  
*Registration No.* 48,608

**Customer No. 20462**